Education
About Us
Working with TipRanks
Follow Us
Theriva Biologics (TOVX)
:TOVX
TOVX Stock Chart & Stats
$0.34
-$0.06(-3.70%)
At close: 4:00 PM EST
$0.34
-$0.06(-3.70%)
Day’s Range― - ―
52-Week Range$0.32 - $2.64
Previous CloseN/A
Volume37.66K
Average Volume (3M)8.88M
Market Cap
$2.80M
Enterprise Value-$6.30M
Total Cash (Recent Filing)$12.12M
Total Debt (Recent Filing)$1.25M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 18, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding9,597,952
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-2.25
Enterprise Value/Revenue-40.91
Enterprise Value/Gross Profit699.95
Enterprise Value/Ebitda0.19
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Financial PositionTheriva has a cash runway into the fourth quarter of 2025, supported by an additional $7.5 million raised from equity financing.
Market InterestThe oncolytic virus space has been gaining traction with investors and is poised for an active period, with Theriva's VCN-01 approach being differentiated and having orphan drug and fast track designations for pancreatic cancer.
Pipeline PotentialVCN-01 has the potential to resensitize tumors to other therapies by degrading tough stromal tissue, which could be advantageous in treating pancreatic cancer.
Bears Say
Clinical Development UncertaintyThe path forward for VCN-01 is unclear, with uncertainty about whether it will progress to a Phase 3 study or if the dosing needs further exploration.
Clinical Study ResultsThe overall data from the P2b pancreatic cancer study was mixed and unimpressive, particularly because the key measure of median overall survival did not meet expectations.
Stock PerformanceThe shares of Theriva Biologics experienced a significant drop of 40% due to the unimpressive data results and concurrent equity financing.
Theriva Biologics News
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $0.32 and its highest was $2.64 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $2.80M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Nov 18, 2025 which is in 23 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Aug 11, 2025. The company reported -$1.93 earnings per share for the quarter, missing the consensus estimate of -$0.775 by -$1.155.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Overvalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.38.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 9,597,952 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$1.93 in its last earnings report, missing expectations of -$0.775. Following the earnings report the stock price went up 13.514%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
Company Description
Theriva Biologics
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.
Technical Analysis
Galmed Pharmaceuticals
―
Matinas BioPharma
―
Qualigen Therapeutics
―
CNS Pharmaceuticals
―
Galecto
―
Ownership Overview
2.72%
Insiders
0.27% Mutual Funds
2.17% Other Institutional Investors
94.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---